PRODUCT

고객만족을 위해 지속적으로 고민하고 혁신하여 최고의 품질을 제공합니다.

search

R&D reagents

Product > R&D reagents
Salmeterol xinafoate, 98% (HPLC)
CAS No V1621-10mg
제품번호 AK Sci.(USA)
제조사 수입산
재고 1 EA
금액 229,000원
포장단위



(+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate





※ 화학명 : Salmeterol xinafoate, 98% (HPLC)

 

※ 등급 : APIs and Bioactives > Adrenergic Agonists

 

※ 판매 포장단위 : 10mg , 50mg

 

※ 화학식 : C36H45NO7

 

※ CAS # : [94749-08-3]

 

 

 

IDENTITY
CAS Registry #:

 

[94749-08-3]

MDL Number: MFCD00897708
MF: C36H45NO7
MW: 603.75
SPECIFICATIONS & PROPERTIES
Purity: 98% (HPLC)
Physical Form: White to off-white powder
Melting Point: 124-142°C
Long-Term Storage:

 

Store long-term at 2-8°C

Shipping: Not Regulated for Shipping

BIOLOGICAL INFO
Application(s): beta2-adrenoceptor agonist

REVIEW
Salmeterol xinafolate is a long-acting beta 2-adrenergic receptor agonist drug that is prescribed for the treatment of asthma and chronic obstructive pulmonary disease(COPD). Salmeterol xinafolate works as a typical beta 2-agonists, causing bronchodilation by relaxing the smooth muscle in the airway so as to treat the exacerbation of asthma. The long duration of action is due to Salmeterol xinafolate initially diffusing into the plasma membrane of the lung cells, and then slowly being released back outside the cell where they can come into contact with the beta-2 adrenoceptors, with the long carbon chain forming an anchor in the membrane. Salmeterol xinafolate is normally prescribed only for severe persistent asthma following previous treatment with a short-acting beta agonist such as salbutamol and is prescribed concurrently with a corticosteroid, such as beclometasone.
REFERENCES
[1] Johnson M. The pharmacology of salmeterol. Lung. 1990;168 Suppl:115-9
[2] Johnson M. Salmeterol: a novel drug for the treatment of asthma. Agents Actions Suppl. 1991;34:79-95.
[3] Jack D. The 1990 Lilly Prize Lecture. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other beta-adrenoceptor agonists. Br J Clin Pharmacol. 1991 May;31(5):501-14.
[4] Brogden RN, Faulds D. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs. 1991 Nov;42(5):895-912.

Risk Description(s)
R36/37/38: Irritating to eyes, respiratory system and skin

Safety Description(s)
S22: Do not breathe dust .
S24/25: Avoid contact with skin and eyes.